Bioxcel therapeutics announces completion of pre-nda meeting with fda for bxcl501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders

Initiated rolling submission of new drug application (“nda”) with u.s. food and drug administration (“fda”)

BTAI Ratings Summary

BTAI Quant Ranking